Robert Nakayama

ORCID: 0000-0003-1985-2169

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study”.

Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study

The Lancet(2025)10.1016/s0140-6736(25)00986-9

N/A

0.707DataRank · unranked

39 citations

Geraldine O’Sullivan Coyne, Pamela L. Wolters, Staci Martin, Said Farschtschi, Ignacio Blanco +38 more

Translational Aspects of Epithelioid Sarcoma: Current Consensus

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2174

N/A

0DataRank · unranked

15 citations

Sophie Postel‐Vinay, Robert Nakayama, Noah Berlow, Andrea Bolzicco, Vincenzo Cerullo +21 more